Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review

por Garon, Edward B., Visseren-Grul, Carla, Rizzo, Maria Teresa, Puri, Tarun, Chenji, Suresh, Reck, Martin
Publicado 2023

Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immedia...

por Paz-Ares, Luis G, Altug, Sedat, Vaury, Alexandra Thareau, Jaime, Jesús Corral, Russo, Francesca, Visseren-Grul, Carla
Publicado 2010

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship

por Nakagawa, Kazuhiko, Garon, Edward B., Gao, Ling, Callies, Sophie, Zimmermann, Annamaria, Walgren, Richard, Visseren-Grul, Carla, Reck, Martin
Publicado 2022

Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 r...

por Nishio, Kazuto, Sakai, Kazuko, Nishio, Makoto, Seto, Takashi, Visseren-Grul, Carla, Carlsen, Michelle, Matsui, Tomoko, Enatsu, Sotaro, Nakagawa, Kazuhiko
Publicado 2023

Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgr...

por Garrido, Pilar, Chouaki, Nadia, Serke, Monika, Giraud, Philippe, Ricardi, Umberto, Vallejo, Carmen, Visseren-Grul, Carla, Soldatenkova, Victoria, Novello, Silvia
Publicado 2017

Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design

por Lal, Rohit, Bourayou, Nawel, Hillerdal, Gunnar, Nicolson, Marianne, Vikstrom, Anders, Lorenzo, Maria, D’yachkova, Yulia, Barriga, Susana, Visseren-Grul, Carla
Publicado 2013

TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

por Le, Xiuning, Molife, Cliff, Leusch, Mark S., Rizzo, Maria Teresa, Peterson, Patrick M., Caria, Nicola, Chen, Yongmei, Gugel, Elena Gonzalez, Visseren-Grul, Carla
Publicado 2022

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Pl...

por Reck, Martin, Paz-Ares, Luis G., de Marinis, Filippo, Molinier, Olivier, Sahoo, Tarini Prasad, Laack, Eckart, John, William, Zimmermann, Annamaria H., Visseren-Grul, Carla, Gridelli, Cesare
Publicado 2014

Association between Gene Expression Profiles and Clinical Outcome of Pemetrexed-Based Treatment in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Exploratory Resul...

por Fennell, Dean A., Myrand, Scott P., Nguyen, Tuan S., Ferry, David, Kerr, Keith M., Maxwell, Perry, Moore, Stephen D., Visseren-Grul, Carla, Das, Mayukh, Nicolson, Marianne C.
Publicado 2014

RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cance...

por Nadal, Ernest, Horinouchi, Hidehito, Shih, Jin-Yuan, Nakagawa, Kazuhiko, Reck, Martin, Garon, Edward B., Wei, Yu-Feng, Kollmeier, Jens, Frimodt-Moller, Bente, Barrett, Emily, Lipkovich, Olga, Visseren-Grul, Carla, Novello, Silvia
Publicado 2021

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

por Nakagawa, Kazuhiko, Nadal, Ernest, Garon, Edward B., Nishio, Makoto, Seto, Takashi, Yamamoto, Nobuyuki, Park, Keunchil, Shih, Jin-Yuan, Paz-Ares, Luis, Frimodt-Moller, Bente, Zimmermann, Annamaria H., Wijayawardana, Sameera, Visseren-Grul, Carla, Reck, Martin
Publicado 2021

Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY

por Nishio, Makoto, Seto, Takashi, Reck, Martin, Garon, Edward B., Chiu, Chao‐Hua, Yoh, Kiyotaka, Imamura, Fumio, Park, Keunchil, Shih, Jin‐Yuan, Visseren‐Grul, Carla, Frimodt‐Moller, Bente, Zimmermann, Annamaria, Homma, Gosuke, Enatsu, Sotaro, Nakagawa, Kazuhiko
Publicado 2020

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC

por Nishio, Makoto, Nishio, Kazuto, Reck, Martin, Garon, Edward B., Imamura, Fumio, Kawaguchi, Tomoya, Yamaguchi, Hiroyuki, Ikeda, Satoshi, Hirano, Katsuya, Visseren-Grul, Carla, Ceccarelli, Matteo, Wijayawardana, Sameera R., Zimmermann, Annamaria, Matsui, Tomoko, Enatsu, Sotaro, Nakagawa, Kazuhiko
Publicado 2022

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset

por Nishio, Kazuto, Seto, Takashi, Nishio, Makoto, Reck, Martin, Garon, Edward B., Sakai, Kazuko, Goto, Koichi, Kato, Terufumi, Nakanishi, Yoichi, Takahashi, Toshiaki, Yamamoto, Nobuyuki, Kiura, Katsuyuki, Ohe, Yuichiro, Tamura, Tomohide, Visseren-Grul, Carla, Frimodt-Moller, Bente, Hozak, Rebecca R., Wijayawardana, Sameera R., Zimmermann, Annamaria, Homma, Gosuke, Enatsu, Sotaro, Nakagawa, Kazuhiko
Publicado 2021